Myths that make support worse
Original guidance written for MenoHealth by its editorial team. · 10 min read · Oct 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on October 13, 2026

Nine things most people believe about menopause that are wrong, what the evidence actually shows, and what to do differently once you know.
In brief
- What this helps with. Unlearning the beliefs that lead supporters to dismiss what she describes.
- One thing to do. Leave the 2002 where it belongs in 2002, explain it but debunk the myths and bad information before her appointment.
- One thing to ask. "What are you actually dealing with, beyond the hot flashes?"
Most of what you know about menopause you absorbed sideways, from jokes, from your mother's silence, from a headline in 2002. Some of it is wrong, and a supporter acting on a myth ends up dismissing the real thing she is describing. A myth is a reason not to take the thing in front of you seriously, so unlearning it is mostly removing the excuse. Here are the nine that cause the most trouble, with what the evidence says and what to do about it.
"It's just hot flashes."
Hot flashes are just one symptom in group out of several. The Greene Climacteric Scale, the clinical framework her MenoScore draws on, has 21 symptoms across psychological, somatic (muscular skeletal), vasomotor and sexual domains. Anxiety, low mood, poor sleep, aching joints, palpitations, poor concentration and loss of interest in sex all count, and many women have several at once. What you do with it is ask what she is actually dealing with.
"It's over when her periods stop."
Menopause is the day twelve months after her last period, and symptoms do not read the calendar. In the Study of Women's Health Across the Nation, among women in the study who had frequent hot flashes, hot flashes and night sweats continued for a median of 4.5 years after the final period. Vaginal dryness and urinary symptoms, together called genitourinary syndrome of menopause, are chronic and tend to progress without treatment. What you do with it is stop treating her last period as a finish line.
"She's too young for this."
The transition most often begins between 45 and 55, and it can start earlier. Loss of ovarian function before 40 has its own name, premature ovarian insufficiency, and its own international clinical guideline, updated in 2024 (Previously premature ovarian failure). A woman of 42 with night sweats and changing cycles is not too young, she is early, and being early makes her more likely to be dismissed. What you do with it is refuse to let her age be the reason her symptoms go unexamined, and if she is under 45, treat a clinician's opinion as more important, because early loss of ovarian function has long-term health consequences beyond symptoms.
"Hormone therapy causes cancer."
In 2002 the Women's Health Initiative stopped its estrogen plus progestin trial early, and the reported rise in breast cancer risk became the headline for a generation. The picture is more detailed, not simply reversed. An 18-year follow-up published in 2017 found that five to seven years of hormone therapy was not associated with higher death rates from any cause, from cardiovascular disease or from cancer. That does not erase the risks attached to particular regimens. Combined estrogen and progestogen therapy carries a small increase in breast cancer incidence that depends on duration and type of therapy, and The Menopause Society's 2022 position statement concludes that for symptomatic women under 60 or within ten years of menopause who have no contraindications, benefits generally outweigh risks, with the decision individual to her history and made with a clinician. Also for women who still have a uterus (womb) Estrogen should not be taken without a progesterone due to risk of endometrial hyperplasia (Pre cancer) What you do with it is leave the 2002 headline out of her appointment, and leave the weighing to the two of them.
"It's all in her head."
Her symptoms have been measured in large studies, even if not every change she notices will turn out to be menopause. In SWAN, women in late perimenopause on average showed a measurable dip in verbal memory and processing speed, and for most women in the study performance recovered after menopause. What you do with it is believe her out loud, in words, because plain belief is rare enough to register.
"She just needs to exercise or lose weight."
The Menopause Society reviewed the evidence for nonhormone approaches in 2023 and found it insufficient to recommend exercise for hot flashes. Exercise is good for her for other reasons, but it is not a treatment for this. The same review lists weight loss among approaches with some evidence, and that is a conversation for her and her clinician. Coming from you, it is a comment on her body and is probably unwelcome.
"Natural remedies are safer."
Natural is a marketing word, not a safety category. The 2023 statement does not recommend supplements or herbal remedies for hot flashes because the evidence does not support them. The FDA does not approve dietary supplements before sale. The manufacturer is responsible for safety and truthful claims, and the agency acts on problems after the product is on the market, so a supplement has not been through the premarket testing a prescription medicine has. What you do with it is not buy her a bottle of anything, and if she takes something, suggest once that a pharmacist or her clinician should know.
"Every woman gets the same version."
In the SWAN cohort, among women who had frequent hot flashes, the median duration ran from 4.8 years in Japanese women to 10.1 years in Black women. Researchers charting symptoms across the transition found four distinct trajectories rather than one. Her mother's version and the version in the joke are not hers. What you do with it is stop comparing, out loud and in your head.
"It's a mood problem, not a medical one."
Low mood in the transition is common and treatable, and it deserves a clinician whether or not menopause is the cause. In SWAN, women were substantially more likely to experience major depression during the transition and early postmenopause than before it, with odds roughly two to four times higher. A joint guideline from The Menopause Society and the National Network of Depression Centers recognizes perimenopausal depression and puts psychotherapy and antidepressants on the front line. Not every mood change is a menopause effect, and it does not have to be one to deserve care. What you do with it is treat persistent low mood or loss of interest as a matter for a healthcare professional, without waiting for a month or a full set of symptoms, and sooner when symptoms are severe, worsening, affecting everyday life or raising safety concerns. If she talks about not wanting to go on, or about harming herself, stay with her and help her reach professional support the same day. The article "When symptoms need help now" in this library covers what to do.
The short version
Related reading
- Hormone therapy, explained for supporters
- Before you buy her a supplement
- When low mood needs professional help
- When symptoms need help now
Frequently asked questions
Is 40 too young for menopause?
Perimenopause can start in the early 40s, so a woman of 42 with night sweats and changing cycles may be early rather than imagining things. The final period itself comes at about 51 on average. Periods stopping for good between 40 and 45 is called early menopause, and before 40 it is premature ovarian insufficiency. Both deserve a clinician's evaluation, because early loss of ovarian function affects bone and heart health.
Is menopause over when periods stop?
No. Menopause is the day twelve months after a woman's last natural period, and symptoms often continue past it. In the Study of Women's Health Across the Nation, women who had frequent hot flashes kept having hot flashes and night sweats for a median of 4.5 years after their final period. Vaginal dryness and urinary symptoms are chronic and tend to progress without treatment. The last period is a milestone, not a finish line.
Does HRT cause cancer?
It depends on the type. Estrogen taken alone raises the risk of uterine cancer in women who still have a uterus, so they are also given a progestogen to protect the lining. Combined therapy carries a small increase in breast cancer risk that grows with longer use. In the Women's Health Initiative's 18-year follow-up, five to seven years of hormone therapy did not raise deaths from cancer or any cause. Her clinician can weigh her own risk.
Sources
- Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29(1):25-31.
- National Institute on Aging. What is menopause? U.S. National Institutes of Health.
- Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015;175(4):531-539. SWAN cohort, n=1,449 women with frequent vasomotor symptoms.
- The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
- Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open. 2024;2024(4):hoae065.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
- The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850-1857.
- The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Consumer update.
- Tepper PG, Brooks MM, Randolph JF Jr, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016;23(10):1067-1074.
- Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychological Medicine. 2011;41(9):1879-1888.
- Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069-1085. Joint guideline of The North American Menopause Society and the National Network of Depression Centers.
Disclaimer
This article is for education and support. It is not medical advice, and it is not a substitute for care from a qualified healthcare provider. Decisions about treatment, including hormone therapy and other prescription medicines, belong to the person experiencing menopause and her clinician. If someone is in immediate danger, contact local emergency services.



